AZ 04 - Azurity Pharmaceuticals
Alternative Names: AZ-04 - Azurity PharmaceuticalsLatest Information Update: 07 Jun 2022
At a glance
- Originator Azurity Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration CNS disorders
Most Recent Events
- 06 Apr 2022 AZ 04 - Azurity Pharmaceuticals is available for licensing as of 06 Apr 2022. https://azurity.com/pipeline/
- 06 Apr 2022 Preregistration in CNS disorders (unspecified route) (Azurity Pharmaceuticals pipeline, April 2022)